Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2016 Jan;16(1):6.
doi: 10.1007/s11892-015-0702-6.

Wolfram Syndrome: Diagnosis, Management, and Treatment

Affiliations
Review

Wolfram Syndrome: Diagnosis, Management, and Treatment

Fumihiko Urano. Curr Diab Rep. 2016 Jan.

Abstract

Wolfram syndrome is a rare genetic disorder characterized by juvenile-onset diabetes mellitus, diabetes insipidus, optic nerve atrophy, hearing loss, and neurodegeneration. Although there are currently no effective treatments that can delay or reverse the progression of Wolfram syndrome, the use of careful clinical monitoring and supportive care can help relieve the suffering of patients and improve their quality of life. The prognosis of this syndrome is currently poor, and many patients die prematurely with severe neurological disabilities, raising the urgency for developing novel treatments for Wolfram syndrome. In this article, we describe natural history and etiology, provide recommendations for diagnosis and clinical management, and introduce new treatments for Wolfram syndrome.

Keywords: Blindness; Deafness; Endoplasmic reticulum stress; Genetic disorder; Neurodegeneration; Type 1 diabetes; Type 2 diabetes; Wolfram syndrome; β cells.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Common clinical manifestations in Wolfram syndrome
Fig. 2
Fig. 2
Development of diagnostics and therapeutics for Wolfram syndrome
Fig. 3
Fig. 3
Power of Wolfram syndrome. It has been established that endoplasmic reticulum (ER) dysfunction and ER stress are critical pathogenic components of Wolfram syndrome. It would be possible to identify biomarkers and treatments targeting ER in mechanistically homogenous Wolfram syndrome patients, which may lead to a breakthrough for treatments of common diseases, such as type 1 diabetes, type 2 diabetes, and neurodegeneration, in which ER dysfunction is involved

References

    1. Wolfram DJ, Wagener HP. Diabetes mellitus and simple optic atrophy among siblings: report of four cases. Mayo Clin Proc. 1938;1:715–8.
    1. Kinsley BT, Swift M, Dumont RH, et al. Morbidity and mortality in the Wolfram syndrome. Diabetes Care. 1995;18(12):1566–70. doi: 10.2337/diacare.18.12.1566. - DOI - PubMed
    1. Barrett TG, Bundey SE, Macleod AF. Neurodegeneration and diabetes: UK nationwide study of Wolfram (DIDMOAD) syndrome. Lancet. 1995;346(8988):1458–63. doi: 10.1016/S0140-6736(95)92473-6. - DOI - PubMed
    1. Barrett TG, Bundey SE. Wolfram (DIDMOAD) syndrome. J Med Genet. 1997;34(10):838–41. doi: 10.1136/jmg.34.10.838. - DOI - PMC - PubMed
    1. Hershey T, Lugar HM, Shimony JS, et al. Early brain vulnerability in wolfram syndrome. PLoS One. 2012;7(7):e40604. doi: 10.1371/journal.pone.0040604. - DOI - PMC - PubMed

Publication types